IMGN News and Press, ImmunoGen Inc. From 11/27/23

2023-11-27 17:41:15 ET Summary ImmunoGen, Inc. expects to convert the Accelerated Approval of its drug Elahere to "Full Approval" in the 1st half of 2024. Potential European approval of Elahere for treatment of patients with FRa-high platinum-resistant ovarian cancer expected late...

2023-11-20 16:28:23 ET More on ImmunoGen ImmunoGen, Inc. (IMGN) Q3 2023 Earnings Call Transcript Analyzing The Acquisition Potential Of ImmunoGen ImmunoGen: Takeda Swoops For Slice Of Elahere - Adding To Valuation Uncertainty? ImmunoGen stock gains 7% amid Q3...

ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will participate in a fireside chat at the upcoming Jefferies London Healthcare Conference. The presentation is scheduled for Novembe...

2023-11-02 16:13:05 ET ImmunoGen, Inc. (IMGN) Q3 2023 Earnings Conference Call November 02, 2023, 08:00 ET Company Participants Anabel Chan - Head, IR Mark Enyedy - President, CEO & Director Isabel Kalofonos - SVP & Chief Commercial Officer Lauren Whi...

2023-11-02 12:43:14 ET More on ImmunoGen Analyzing The Acquisition Potential Of ImmunoGen ImmunoGen: Takeda Swoops For Slice Of Elahere - Adding To Valuation Uncertainty? ImmunoGen Stock Falls, Elahere Growth Contrasts (Rating Upgrade) ImmunoGen Q3 2023 Earni...

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

2023-11-02 06:31:36 ET More on ImmunoGen Analyzing The Acquisition Potential Of ImmunoGen ImmunoGen: Takeda Swoops For Slice Of Elahere - Adding To Valuation Uncertainty? ImmunoGen Stock Falls, Elahere Growth Contrasts (Rating Upgrade) ImmunoGen Q3 2023 Earni...

Continued Strong Demand for ELAHERE; US Net Sales of $105.2 Million in Q3 ELAHERE MAA in FRα-Positive Platinum-Resistant Ovarian Cancer Accepted by EMA; sBLA to Support Full Approval in US Submitted to FDA PICCOLO Trial of ELAHERE in Platinum-Sensitive Ovarian Cancer Meets ...

ImmunoGen Inc. (IMGN) is expected to report $0.02 for Q3 2023

2023-11-01 12:52:35 ET More on ImmunoGen Analyzing The Acquisition Potential Of ImmunoGen ImmunoGen: Takeda Swoops For Slice Of Elahere - Adding To Valuation Uncertainty? ImmunoGen Stock Falls, Elahere Growth Contrasts (Rating Upgrade) ImmunoGen's ovarian can...